Literature DB >> 21470666

Evidence of increased platelet reactivity in the first six months after acute ST segment elevation myocardial infarction.

Giancarla Scalone1, Ilaria Coviello, Lucy Barone, Irma Battipaglia, Cristina Aurigemma, Giulia Careri, Gaetano Pinnacchio, Pierpaolo Tarzia, Gaetano Antonio Lanza, Filippo Crea.   

Abstract

INTRODUCTION: Platelets play a crucial role in the pathogenesis of acute coronary syndromes. Accordingly, previous studies showed increased platelet reactivity on admission in these patients. In this study we assessed platelet reactivity at short-medium term follow-up in patients with ST-segment elevation acute myocardial infarction (STEMI).
MATERIALS AND METHODS: Fifty-nine patients (58 ± 11 years, 45 men), treated with primary angioplasty, were studied 1 month after STEMI. Thirty-five patients were retested at 6 months. Twenty matched patients with stable coronary artery disease served as controls. Platelet reactivity was assessed by flow cyometry at rest and at peak exercise, with and without adenosine diphosphate (ADP) stimulation, by measuring monocyte-platelet aggregates (MPAs) and glycoprotein IIb/IIIa (CD41) expression in the MPA gate, and CD41 and fibrinogen receptor (PAC-1) expression in the platelet gate.
RESULTS: Compared to controls, basal MPAs and CD41 in the MPA gate were higher in STEMI patients both at 1 month (p = 0.001 and p = 0.002, respectively) and at 6 months (p = 0.03 and p = 0.01, respectively). Basal CD41 and PAC-1 expression was also higher in STEMI patients at the two assessments compared to controls (P<0.001 for both). Exercise induced a similar increase in platelet reactivity in patients and controls. ADP induced a higher increase in CD41 platelet expression in STEMI patients compared to controls both at 1 and 6 months (P < 0.001).
CONCLUSION: Platelet reactivity is increased in the first 6 months after STEMI. The persistence of increased platelet reactivity in this time period may play a role in the early recurrence of coronary events after STEMI.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21470666     DOI: 10.1016/j.thromres.2011.03.018

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.

Authors:  Henrik Wagner; Christian Lood; Catharina Borna; Olof Gidlöf; Lennart Truedsson; Patricia Brown; Chunmei Zhou; Kenneth Winters; Joseph A Jakubowski; David Erlinge
Journal:  J Thromb Thrombolysis       Date:  2016-10       Impact factor: 2.300

2.  Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor.

Authors:  Alon Eisen; Hila Lerman-Shivek; Leor Perl; Eldad Rechavia; Dorit Leshem-Lev; Noa Zemer-Wassercug; Oshrat Dadush; Shirit Kazum; Pablo Codner; Ran Kornowski; Eli I Lev
Journal:  J Thromb Thrombolysis       Date:  2015-07       Impact factor: 2.300

3.  Characterization of the platelet transcriptome by RNA sequencing in patients with acute myocardial infarction.

Authors:  John D Eicher; Yoshiyuki Wakabayashi; Olga Vitseva; Nada Esa; Yanqin Yang; Jun Zhu; Jane E Freedman; David D McManus; Andrew D Johnson
Journal:  Platelets       Date:  2015-09-14       Impact factor: 3.862

4.  Effect of α-lipoic acid on platelet reactivity in type 1 diabetic patients.

Authors:  Roberto Mollo; Francesco Zaccardi; Giancarla Scalone; Giuseppe Scavone; Paola Rizzo; Eliano Pio Navarese; Andrea Manto; Dario Pitocco; Gaetano Antonio Lanza; Giovanni Ghirlanda; Filippo Crea
Journal:  Diabetes Care       Date:  2012-01-06       Impact factor: 19.112

5.  Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?

Authors:  Alessandro Lucchesi; Silvia Carloni; Serena De Matteis; Martina Ghetti; Gerardo Musuraca; Monica Poggiaspalla; Accursio F Augello; Giulio Giordano; Pier P Fattori; Giovanni Martinelli; Roberta Napolitano
Journal:  Br J Haematol       Date:  2019-12-02       Impact factor: 6.998

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.